Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-04-03

Clinical Trial Update: Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of AG-013736 (axitinib) in patients with refractory metastatic renal cell carcinoma has completed, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AG-013736

Snippet

Sponsor: Pfizer | Conditions: Kidney Neoplasms, Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2012-04-03